The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
AACR 2024 | Antibody-drug conjugates for the treatment of lymphoma
Pau Abrisqueta, MD, PhD, Vall d´Hebron University Hospital, Barcelona, Spain, briefly comments on antibody-drug conjugates (ADCs) for treating lymphoma. Polatuzumab vedotin is the most thoroughly investigated ADC in this context, but data also exist for loncastuximab tesirine, and other ADCs are currently being evaluated. Dr Abrisqueta also emphasizes the importance of exploring a diversity of targets when developing new ADCs. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
